BIO-key International, Inc. (BKYI) Q2 2025 Earnings Conference Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong revenue growth (49% increase), reduced SG&A expenses, and a significant reduction in note payable. Despite a slight decline in gross margin, the overall financial performance is robust. The Q&A section reveals confidence in future growth, especially in defense and cybersecurity markets. Although management avoided specific guidance, the positive contract activity and expected breakeven achievement provide a positive outlook. The lack of market cap data suggests a neutral to positive reaction, but given the strong financials and growth prospects, a positive sentiment is warranted.
Key Financial Performance
Revenue Q2 '25 revenue increased 49% to $1.7 million versus $1.1 million in Q2 '24. The increase was driven by a $458,000 rise in hardware revenue due to additional deployments of finger biometric scanners for a large long-time customer. License fee revenue increased 4%, reflecting a growing base of subscription contracts. Service revenue increased 11%, largely due to customer service for a large customer upgrade.
Gross Profit Q2 '25 gross profit increased by $354,000 or 40% to $1.2 million from $0.9 million in Q2 '24. This was due to the increase in total revenue, offset by a modest decline in gross margin to 73% in Q2 '25 versus 77% in Q2 '24. The margin decrease was attributed to a large increase in hardware revenue as a percentage of sales, which carries a lower margin than license fees and services.
SG&A Expenses SG&A expenses were reduced by 13.5% year-over-year in Q2 '25, resulting from reductions in administrative sales personnel costs and professional service fees. This improvement was partially offset by higher research and development costs to support the development of next-generation products such as the PortalGuard upgrade and exploration of new product lines.
Note Payable The note payable was reduced to a balance of $447,000 from $1.5 million at the end of December 2024, reflecting a significant reduction in debt.
Current Assets As of June 30, 2025, current assets were $4 million, including $2.3 million in cash, up from year-end current assets of $1.9 million, which included $438,000 in cash. Accounts receivable also increased by 37% year-over-year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
PortalGuard upgrade: Higher R&D costs were incurred to support the development of next-generation products, including the PortalGuard upgrade.
National Bank of Mozambique: Secured a major identity and access management deployment in partnership with Runlevel.
Defense intelligence market: Extended penetration based on IAM and biometric-enabled solutions, including deployments for an international defense agency and a Middle East police force.
EMEA regions: Refocused efforts on BIO-key branded solutions, leading to improved traction and positive year-over-year revenue comparisons.
North America: Continued strong position in higher education, healthcare, public sector, finance, and insurance markets.
Revenue growth: Q2 2025 revenue increased by 49% year-over-year to $1.7 million, driven by hardware and service revenue growth.
Expense reduction: SG&A expenses reduced by 13.5% year-over-year, offsetting increased R&D investments.
Gross profit: Increased by 40% year-over-year to $1.2 million, though gross margin slightly declined to 73%.
Debt reduction: Reduced note payable balance to $447,000 from $1.5 million at the end of December 2024.
Sales and marketing strategy: Developed a new marketing program to articulate unique capabilities and value proposition, revitalized North American sales efforts, and transitioned back to an in-office model for sales and marketing teams.
Cost reduction initiatives: Continued efforts to lower breakeven level and support path to positive cash flow and profitability.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Competition: The company acknowledges the complexity and competition in its space, which necessitated the development of a new marketing program to better articulate its unique capabilities and value proposition. This indicates competitive pressures that could impact market share and sales.
Strategic Execution Risks: The transition away from licensed Swivel Secure solutions to BIO-key branded solutions in the EMEA region requires rebuilding the opportunity pipeline and channel strategy, which takes time and could delay revenue growth.
Economic and Geopolitical Uncertainties: The company is exposed to economic and geopolitical uncertainties, particularly in the EMEA region, which could impact its operations and financial performance.
Supply Chain and Cost Management: The company has reduced SG&A expenses and is focusing on cost management to lower its breakeven level. However, higher R&D costs and the need for investments in next-generation products could strain financial resources.
Customer Concentration Risk: A significant portion of revenue growth is attributed to large customers, such as the deployment of biometric scanners and service upgrades for long-time customers. This reliance on a few key customers could pose risks if these relationships are disrupted.
Regulatory and Security Risks: The company operates in sectors like defense and cybersecurity, which are subject to stringent regulatory requirements and security risks. Any failure to comply or breaches could adversely affect operations and reputation.
Sales and Operational Challenges: The company is revitalizing its North American sales efforts by recruiting new leadership and moving back to an in-office model. These changes could face resistance or delays, impacting sales performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: BIO-key expects improved top and bottom-line results in 2025 and beyond, supported by strategic business development initiatives and a growing base of global channel partners, customers, and reference accounts.
Margin Projections: The company anticipates enhanced margins from the EMEA Group in the back half of 2025 due to a focus on BIO-key solutions, which provide greater control and stronger gross margins.
Market Trends: Increased defense and security spending by NATO members and the EU, with a focus on cybersecurity, is expected to drive demand for BIO-key's solutions. The EMEA region is showing improved traction and interest in BIO-key's biometric capabilities.
Business Segment Performance: The company is optimistic about growth opportunities in the EMEA regions and North America, particularly in higher education, healthcare, public sector, finance, and insurance segments. A new marketing program and revitalized sales efforts are expected to support growth.
Operational Changes: BIO-key is transitioning back to an in-office model for sales, business development, and marketing teams to enhance collaboration and competitiveness.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:With the increased cost for sales and support team on cyber defense and increased R&D, should we expect the recent trend towards reduced operating expenses to reverse?
A:No, the recent trend towards reduced operating expenses is not expected to reverse. There was a $300,000 blip in Q2 due to specific events, but the expense run rate from the start of the year is expected to continue through Q3 and Q4.
Q:Can you give additional color on what meaningful contract activity in the first half of next year means, particularly in cybersecurity in Europe?
A:The company has already closed contracts in late last quarter and this quarter, which they cannot discuss in detail. They provide a unique identity and access management platform with biometric security, which positions them well in the defense and intelligence markets. They are expanding their efforts in Europe and the Middle East, where increased defense spending is expected to drive growth.
Q:Have you received income from the contracts you mentioned, or are they scheduled for the first half of next year?
A:Both. Some contracts closed in Q3 will be reflected in Q3 results, while others will generate revenue through the end of this year and into next year. These are multiyear spending initiatives.
Q:Do you expect these contracts to ramp up significantly in the first half of next year to help achieve breakeven?
A:Yes, the contracts are expected to grow iteratively, with increasing opportunities and customer base. The company has seen similar growth patterns with other defense ministry customers, leading to multimillion-dollar sales over time. Gross margins remain strong at 70-80%.
Q:Will there be growth in the third quarter, or might there be a slowdown before ramping up in the fourth quarter?
A:The company does not provide guidance but noted that the European summer slowdown impacts enterprise markets more than defense and intelligence sectors. They are encouraged by their pipeline and opportunities.
Q:How much of the reserve inventory did you sell, and how much is left?
A:The company is selling reserve inventory every quarter and aims to move the bulk of it by year-end. However, they did not disclose how much inventory is left.
Q:Do hardware sales lead or lag software sales?
A:Hardware and software sales usually occur together in initial contracts. Expansion contracts may include additional software and hardware. For example, a large defense ministry customer deployed 40,000 touchpoints and continues to add users.
Q:Can you provide an update on Nigeria or Africa?
A:The company is focusing on supporting core products in Africa through partners. They closed two banking deals in the first half of the year and have another in the pipeline. The focus is on commercial enterprise markets with biometric solutions.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on certain contracts, including names and exact revenue figures. They also did not disclose the remaining reserve inventory amount. Additionally, they declined to provide guidance on growth expectations for Q3 and Q4.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Action Europe
America position
BIO financials
Bank Mozambique
CEO Jones
Ceci review
Cecilia Welch
Chief Financial
Corporate Participant
ET Cecilia
EU effort
EUR defense
East police
Europe SAFE
Financial Officer
GDP spending
Group marketing
Inc Conference
International Inc
International Instructions
addition
channel partner
cybersecurity
health care
investment
network
reference account
sale effort
strength
traction
value proposition
BKYI Transcript
BIO-key International, Inc. (BKYI) Q1 2026 Earnings Call Transcript
Positive5-18
The earnings call reveals strong revenue growth expectations, improved net loss, and positive market trends in authentication solutions. Product developments and strategic focuses align with market needs, and financial health is stable with no funding issues. The Q&A session highlights optimism for future opportunities and a strong pipeline, despite some challenges in U.S. contracts. Overall, the positive elements outweigh the negatives, suggesting a likely positive stock price movement.
BIO-key International, Inc. (BKYI) Q4 2025 Earnings Call Transcript
Positive3-31
The earnings call highlights improved financial metrics, including increased gross margins and cash position, despite a slight increase in net loss. The Q&A reveals optimistic guidance with potential growth in strategic sectors and regions, supported by partnerships. The announcement of PortalGuard Version 7 and a significant contract renewal further bolster the outlook. While some uncertainties remain, such as the reverse stock split, the overall sentiment leans positive due to strong future prospects and strategic initiatives.
BIO-key International, Inc. (BKYI) Q3 2025 Earnings Call Transcript
Unknown11-14
The earnings call presents a mixed picture. Financial performance shows a slight decline in gross margin and increased net loss, but cash position improved significantly. Product development is positive with new contracts and high-quality offerings. Market strategy is strong with potential expansions and partnerships. However, flat revenues and management's vague responses in the Q&A raise concerns. The strategic plan indicates optimism for future growth, but immediate financial metrics and unclear guidance limit positive sentiment. Overall, the stock reaction is likely neutral in the short term, balancing positive long-term prospects with current challenges.
BIO-key International, Inc. (BKYI) Q2 2025 Earnings Conference Call Transcript
Positive8-13
The earnings call highlights strong revenue growth (49% increase), reduced SG&A expenses, and a significant reduction in note payable. Despite a slight decline in gross margin, the overall financial performance is robust. The Q&A section reveals confidence in future growth, especially in defense and cybersecurity markets. Although management avoided specific guidance, the positive contract activity and expected breakeven achievement provide a positive outlook. The lack of market cap data suggests a neutral to positive reaction, but given the strong financials and growth prospects, a positive sentiment is warranted.
BKYI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
